Hydroxycarbamid

Phase 2Small molecule

TTheravia

Hydroxycarbamid is one of 53 small molecule programs targeting Sickle Cell Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sickle Cell DiseaseRecruiting

R/R AMLNot yet recruiting

Sickle Cell DiseasePhase 2

Recruiting

R/R AMLPreclinical

Not yet recruiting

Competition

Competitive Landscape

91 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Phase 3

14 2

Ritalin

Novartis

Phase 3

2 3

Toradol

JJavelin Pharmaceuticals

Phase 3

2 4

Fludara

Sanofi

Phase 2

10 5

Cellcept

Roche

Phase 2

6 6

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 7

PIASKY

Roche

Phase 3

2 8

Tepadina

Jazz Pharmaceuticals

Phase 2

4 9

Rapamune

PPrism Pharmaceuticals

Nipent

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Sickle Cell Disease

NCT06578507

Q3 2034

PreclinicalNot yet recruiting

R/R AML

NCT07766850

Clinical

Trials by Indication[1]

Retinal Vein Occlusion1 trial

Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

Unknown status·—·Phase 2·NCT02957760·30 enrolled

Sickle Cell Disease1 trial

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)

Recruiting·TTheravia·Phase 2·NCT06578507·50 enrolled

R/R AML1 trial

FLAsH-IV-AML: A Phase I/II Multi-center Study to Assess the Tolerability and Efficacy of the Addition of Hydroxyurea to Salvage Treatment With Fludarabine, Ara-C, Idarubicin and Venetoclax for Adults With Relapsed or Refractory Acute Myeloid Leukemia

Not yet recruiting·CChrister C Nilsson·Preclinical·NCT07766850·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Hydroxycarbamid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydroxycarbamid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydroxycarbamid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Theravia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTheravia

Hydroxycarbamid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2034

Trials by Indication[1]

Retinal Vein Occlusion1 trial

Sickle Cell Disease1 trial

R/R AML1 trial

References

Drug Info

Quick Facts

Related News